U.S. Markets closed

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
40.66+0.08 (+0.21%)
At close: 3:59PM EDT

40.66 +0.01 (0.02%)
After hours: 5:24PM EDT

People also watch
AZNNVSSNYLLYBMY
  • J
    Joe
    Joe
    After owning this for years I've grow accustom to the 45 - 38 trading range. As long as they keep paying fat dividends, I wouldn't mind if traders keep this range going for the next 10 years. Just buy and hold dividends add up!
  • A
    Ameen
    Ameen
    .45 cents soon
  • r
    romypostit
    romypostit
    just decided to keep this stock, , they're bringing in the power of artificial intelligence to work in research and developement. that's powerful since human genome complete mapping i think maybe
  • T
    Tony
    Tony
    Any announcement yet for approval of Shingles?
  • r
    roger
    roger
    FDA unanimously votes to approve GSK's HIV vaccine today and the stock price is down?
  • S
    Scott
    Scott

    It is happier to be sometimes cheated than not to trust. http://dataunion.tistory.com/6978

    MAY-2016 GlaxoSmithKline plc NYSE : GSK Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is -0.1 In other words, the correlation coefficient of the other stocks
    dataunion.tistory.com
  • J
    Julia
    Julia

    GSK, looks to be overvalued at this price check out https://hotstocks123.blogspot.com, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.

  • T
    Tony
    Tony
    Moving to October 24 nevermind.
  • B
    BioLover
    BioLover

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • A
    Anonymous
    Anonymous
    GSK stock is undervalued now. R&D change is positive. I am seeking for stable EPS and revenue in this overvalued market.
  • J
    Joe
    Joe
    Don't buy GSK if you are looking for a stock split or buyout, I guarantee you will be chased out of this stock when traders want to drop it back in the 30's, happens all the time. Buy it if you are looking for a long term nice steady income buy GSK, and Always buy more when it drops below 40. I have been holding GSK since 2003 and couldn't be happier.
  • m
    mark
    mark
    $AGEN conversation
    I heard today the FDA Ad Comm to review and make recommendations on safety, effectiveness of $GSK Shirgrix vaccine with $Agen adjuvant on Sep 13.

    Any opinions on this?
  • r
    romypostit
    romypostit
    does GSK make polio vaccine,i know Great Britain is donating hundreds of million dollars to complete eradication of polio.very good move, citizens should be proud of their country
  • A
    Andrew
    Andrew

    The new CEO Emma Walmsley is going to eclipse Marissa Mayer as a CEO and make GSK into #1 pharma soon
    The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI
    https://endpts.com/the-big-revamp-at-glaxosmithkline-rd-includes-a-new-collaboration-on-ai/

    The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI
    A few weeks ago, when GlaxoSmithKline said it had recruited Pfizer vet Tony Wood to run the platform tech and science group in the pharma R&D operation, the company noted that he was taking the place of John Baldoni, a senior research exec who was la
    endpts.com
  • A
    Anonymous
    Anonymous
    Fortunately, I did not buy GSK yesterday to get today's dividend of $0.49. I would lose additional $0.3. Not worth it. Short term momentum is negative. I expect the stock will continue down with no upward news.
  • A
    Anonymous
    Anonymous
    Some products made tiny sales. Reshape R&D necessary. But it takes long time. Short term, negative. Heading to $38.
  • J
    John
    John
    ...going to realize some return for its shareholders??? WHEN?
  • d
    desert rat
    desert rat
    GSK has all the right parts and pieces to put it on top, then again - so did Kodak. I'm a long time holder of this disappointing stock and I sure hope changes in management makes some measurable difference to its performance.
  • J
    John
    John
    Wonder what's today's excuse for the big pre-market drop in GSK's share price?? Perhaps paying huge bonuses to their less-than-able executives and senior management?? When is this poor excuse for a pharmaceutical company
  • r
    roger
    roger
    CEO is moving the company away from development of cures or rare exotic diseases for which there is little commercial potential to development of drugs to treat diseases that affect a large population that have far greater market potential. It will take a few years to see the benefits of this change, but is the right decision. Buy GSK as an investment, not a day trade for a quick profit.